Cerenis and Novasep get 10.7 million-euro funding from the French government for the development of CER-001

27 July 2010

French companies Cerenis Therapeutics, which is developing novel high-density lipoprotein (HDL) therapies to treat cardiovascular and other metabolic diseases, and Groupe Novasep, a supplier of manufacturing solutions to the life sciences industries, have received government funding of 10.7 million euros ($13.7 million) through France's innovation agency (OSEO) to finance the development of CER-001, a Cerenis HDL mimetic. The OSEO operates under the authority of the Ministry of Economy, Finance and Employment, and the Ministry for Higher Education and Research.

CER-001 represents a promising new approach in the fight against atherosclerotic cardiovascular disease and has shown strong preclinical efficacy in promoting reverse lipid transport, a natural cardioprotective mechanism by which excess lipids are removed from peripheral tissues and from within atherosclerotic plaques then taken to the liver for elimination. The program is currently in Phase 1 clinical development for the treatment of post-acute coronary syndrome patients.

The funding from the OSEO will allow the further progression of Cerenis' novel HDL therapy for orphan disease applications, which represent a large area of unmet need and the potential for an accelerated development pathway.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical